

In the Claims:

Please cancel Claims 1-24, 29, and 30 without prejudice to applicants' right to file divisional applications directed to the subject matter thereof.

25. (Amended) A method for determining a level or pattern of a carcinogenesis biomarker in a cell comprising:

- (A) incubating, under conditions permitting nucleic acid hybridization, a marker nucleic acid molecule, said marker nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ NOS: 280 and 488 or complements thereof, with a complementary nucleic acid molecule obtained from said cell, wherein nucleic acid hybridization between said marker nucleic acid molecule, and said complementary nucleic acid molecule obtained from said cell permits the detection of said carcinogenesis biomarker;
- (B) permitting hybridization between said marker nucleic acid molecule and said complementary nucleic acid molecule obtained from said cell; and
- (C) detecting the level or pattern of said complementary nucleic acid, wherein the detection of said complementary nucleic acid is predictive of the level or pattern of said carcinogenesis biomarker.

31. (Amended) A method for measuring the carcinogenicity of a composition comprising:

- (A) culturing a cell line;
- (B) exposing said cell line to said composition; and
- (C) determining the presence or absence of mRNA which substantially hybridizes to an at least one nucleic acid sequence selected from the group